DENTSPLY SIRONA (NASDAQ: XRAY) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. OraSure Technologies does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.
Volatility & Risk
DENTSPLY SIRONA has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Valuation & Earnings
This table compares DENTSPLY SIRONA and OraSure Technologies’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DENTSPLY SIRONA||$3.84 billion||3.65||$823.80 million||($3.47)||-17.60|
|OraSure Technologies||$135.07 million||8.69||$23.92 million||$0.54||36.57|
DENTSPLY SIRONA has higher revenue and earnings than OraSure Technologies. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for DENTSPLY SIRONA and OraSure Technologies, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DENTSPLY SIRONA presently has a consensus price target of $65.63, suggesting a potential upside of 7.46%. OraSure Technologies has a consensus price target of $17.25, suggesting a potential downside of 12.66%. Given DENTSPLY SIRONA’s higher probable upside, equities research analysts plainly believe DENTSPLY SIRONA is more favorable than OraSure Technologies.
This table compares DENTSPLY SIRONA and OraSure Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
93.9% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 92.9% of OraSure Technologies shares are owned by institutional investors. 2.0% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 6.4% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
OraSure Technologies beats DENTSPLY SIRONA on 9 of the 16 factors compared between the two stocks.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.
OraSure Technologies Company Profile
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.
What are top analysts saying about DENTSPLY SIRONA Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DENTSPLY SIRONA Inc. and related companies.